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Antibody-mediated selective targeting of oral 
vaccines to epithelial CD13
Enterotoxigenic Escherichia coli (ETEC) are a major cause of intestinal infections in
neonatal and recently weaned piglets, resulting in diarrhea, morbidity and mortality. To
achieve successful immunity against intestinal pathogens, mucosal immunity must be
induced (Fig.1). Oral vaccination holds much promise in this regard, but is difficult to
achieve. Antigens not only have to cross the epithelial barrier, but must also circumvent
the default tolerogenic immune response present in the gastro-intestinal tract.
A possible strategy to overcome these problems inherently associated with oral
vaccination is by selectively delivering antigens to specific intestinal cell populations.
Especially the targeting of vaccine antigens to epithelial receptors, such as CD13, looks
promising in this regard (Fig.2).
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Introduction
A novel vector was designed that allowed the expression of GFP and antibody under a
single promotor using the 2A peptide cleavage sequence (Fig.3). This design allowed the
rapid selection of high producing cell lines using single cell sorting in under 2 months.
Clones producing recombinant antibody at concentrations of >60 mg/L were obtained.
Several antibody-antigen constructs targeting CD13 were developed containing a porcine
IgA Fc-domain, linked to the FedF or TetC antigens. These recombinant antibodies showed
stable expression and similar binding and uptake characteristics, compared to the original
monoclonal αCD13 antibody (Fig.4).
Next, these constructs will be assessed for their ability to induce a protective mucosal
immune response against the linked antigens in an in vivo trial.
Results
Targeting of recombinant antibody-antigen constructs to CD13 could potentially induce a
protective mucosal immune response against an antigen of interest. In this project, we
aimed to develop engineered porcine IgA-Fc antibodies, linked to the FedF or TetC
antigens from F18+ E. coli and C. tetani respectively, in order to induce a protective
mucosal immune response towards these antigens. To enable efficient production at
large scale, a novel expression system was used, combining 2A peptide cleavage and
single cell sorting to assist in rapid production of our recombinant antibody constructs.
Aim
Fig.4 Recombinant antigen-antibody constructs.
(A) Silver stain and (B) Western blot images of recombinant antibody-antigen constructs with the porcine IgA heavy
chain (HC), linked to the FedF (HC-FedF) or TetC (HC-TetC) antigens. These constructs (Green) showed stable binding
and uptake on (C) intestinal tissue and (D) an APN-expressing cell line.
Fig.3 Recombinant antibody expression system. Starting with vector design, transfection, sorting,
selection of best producing clones and antibody production + purification. *: Post-translational cleavage.
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Fig.2 Endocytosis of monoclonal antibodies targeted to CD13.
(A) In vitro binding (Red) and endocytosis (Green) of monoclonal antibodies with a CD13-expressing cell line and (B)
ex vivo binding and endocytosis of monoclonal antibodies (Green) by enterocytes (Red) in ileal explant tissue. (Blue:
Hoechst)
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Fig.1 Intestinal mucosal immune response. Antigens are taken up by dendritic cells and presented to
immune effector cells in the Peyer’s patches or mesenteric lymph nodes. The mucosal immune response is
characterized by the production and secretion of secretory IgA (SIgA) by plasma cells. www.b-cell-design.com
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